Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSNutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorderActive, not recruitingPhase 2 / Phase 32026-03-06NCT04057898

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
MediciNova2

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Augusta UniversityAugustaUnited States57
Duke UniversityDurhamUnited States91
Hennepin Healthcare Research InstituteMinneapolisUnited States6
Hopital de L'Enfant-Jesus, CHU de Quebec-Universite LavalQuébecCanada1
Indiana University IU Health Neuroscience CenterIndianapolisUnited States1
Johns Hopkins UniversityBaltimoreUnited States150
Lehigh Valley Health NetworkAllentownUnited States35
Mayo ClinicJacksonvilleUnited States122
McMaster University Medical CenterHamiltonCanada1
Montreal Neurological Institute and HospitalMontrealCanada10
Sunnybrook Research InstituteTorontoCanada36
SUNY Upstate Medical UniversitySyracuseUnited States68
University Of Alberta HospitalEdmontonCanada6
University of CaliforniaOrangeUnited States2
University of Saskatchewan - Sastakoon HospitalSaskatoonCanada1
University of Virginia Health SystemCharlottesvilleUnited States57